Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.043
Neutral
RSI(14)
49.158
Neutral
STOCH(KDJ)(9,3,3)
38.684
Neutral
ATR(14)
0.751
Low Volatility
CCI(14)
-0.362
Neutral
Williams %R
38.057
Buy
TRIX(12,20)
-0.095
Sell
StochRSI(14)
69.814
Buy
Mediwound Ltd
MDWD17.790USD
+0.570+3.31%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
228.09MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Mediwound Ltd
Currency: USD Updated: 2026-02-06Key Insights
Mediwound Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 60 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 31.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Mediwound Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Mediwound Ltd Highlights
StrengthsRisks
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Growing
The company is in a growing phase, with the latest annual income totaling USD 20.22M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 20.22M.
Undervalued
The company’s latest PE is -9.62, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 6.98M shares, increasing 18.62% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 96.88K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.19.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
31.500
Target Price
+82.93%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Mediwound Ltd is 8.19, ranking 80 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 5.43M, representing a year-over-year increase of 24.66%, while its net profit experienced a year-over-year increase of 74.21%.
Score
Financials
8.52
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.72
Operational Efficiency
10.00
Growth Potential
7.48
Shareholder Returns
7.24
Mediwound Ltd's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Mediwound Ltd is 6.31, ranking 127 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -9.62, which is -73.50% below the recent high of -2.55 and -138.73% above the recent low of -22.96.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 60/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Mediwound Ltd is 8.33, ranking 43 out of 159 in the Pharmaceuticals industry. The average price target is 32.00, with a high of 39.00 and a low of 25.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
31.500
Target Price
+82.93%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Mediwound Ltd
MDWD
6
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Mediwound Ltd is 7.47, ranking 55 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 19.31 and the support level at 16.26, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
17.770
Buy
MA10
17.901
Sell
MA20
17.569
Buy
MA50
18.133
Sell
MA100
18.087
Sell
MA200
18.603
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Mediwound Ltd is 5.00, ranking 73 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 54.40%, representing a quarter-over-quarter increase of 22.04%. The largest institutional shareholder is PRFDX, holding a total of 599.38K shares, representing 4.67% of shares outstanding, with 225.72% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Clal Biotechnology Industries Ltd
Investor AB
Yelin Lapidot Provident Funds Management Ltd
Rosalind Advisors, Inc.
HOLD Alapkezelo Zrt
Israel Biotech Fund
BlackRock Institutional Trust Company, N.A.
Meitav Investment House Ltd
Deep Insight Limited Partnership
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Mediwound Ltd is 5.33, ranking 68 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.14. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.14
VaR
+5.63%
240-Day Maximum Drawdown
+26.93%
240-Day Volatility
+49.45%
Return
Best Daily Return
60 days
+6.21%
120 days
+13.26%
5 years
+35.08%
Worst Daily Return
60 days
-7.86%
120 days
-7.86%
5 years
-27.84%
Sharpe Ratio
60 days
+0.34
120 days
+0.01
5 years
+0.12
Risk Assessment
Maximum Drawdown
240 days
+26.93%
3 years
+48.57%
5 years
+82.04%
Return-to-Drawdown Ratio
240 days
-0.04
3 years
+0.32
5 years
-0.11
Skewness
240 days
+0.29
3 years
+1.83
5 years
+0.58
Volatility
Realised Volatility
240 days
+49.45%
5 years
+76.22%
Standardised True Range
240 days
+4.40%
5 years
+5.37%
Downside Risk-Adjusted Return
120 days
+2.37%
240 days
+2.37%
Maximum Daily Upside Volatility
60 days
+26.18%
Maximum Daily Downside Volatility
60 days
+30.23%
Liquidity
Average Turnover Rate
60 days
+0.61%
120 days
+0.67%
5 years
--
Turnover Deviation
20 days
+18.51%
60 days
-16.64%
120 days
-9.16%
Peer Comparison
Pharmaceuticals
Mediwound Ltd
MDWD
7.19 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
